RESTORE-1 Study of Gene Therapy VY-AADC Suspends Patient Screening Due to COVID-19 Pandemic
The Phase 2 RESTORE-1 trial testing the investigational gene therapy VY-AADC has suspended the screening and enrollment of new Parkinson’s disease patients to evaluate the impact of the COVID-19 pandemic on the study’s protocols and on the safety of participants, Voyager Therapeutics has announced. Patient enrollment…